plaque psoriasis
Advertisement
The results of two randomized clinical trials found that risankizumab was associated with improved symptoms, mental ...
Achieving skin clearance in a timely manner is important for patients with moderate-to-severe plaque psoriasis.
In a new study, researchers compared the safety and efficacy of guselkumab, a fully human interleukin-23 antibody ...
Interleukin-23 inhibitor guselkumab is used to treat adult patients with moderate-to-severe plaque psoriasis.
AbbVie’s drug Skyrizi (risankisumab) has been recommended by the United Kingdom’s National Institute for Health and ...
AbbVie’s drug Skyrizi (risankisumab) has been recommended by the United Kingdom’s National Institute for Health and ...
The Food and Drug Administration (FDA) has approved calcipotriene (Sorilux) to treat adolescents with plaque psoriasis. ...
The Food and Drug Administration (FDA) approved a second biosimilar for etanercept (ENBREL, Amgen).
...
Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, learn about a ...
Risankizumab-rzaa has received approval from the Food and Drug Administration (FDA) in the treatment of ...
In a recent trial, treatment with ixekizumab was more effective in active psoriatic arthritis (PsA) patients ...
Risankizumab is a humanized IgG1 monoclonal antibody. It binds to the p19 subunit of interleukin-23, thus inhibiting ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.